Abstract
18-Fluorodeoxyglucose (18FDG) positron emission tomography (PET) coregistered with computed tomography (CT) has been well validated in staging and monitoring treatment response in a wide range of oncological conditions; however, recently, there has been emerging utility in the assessment of inflammatory conditions. Here we present an unusual and important manifestation of metabolically active IgG4 disease affecting the coronary arterial circulation incidentally detected on 18FDG-PET/CT, with a quantitative reduction in maximum standardized uptake values (SUVmax) on follow-up 18FDG-PET/CT studies and normalization of target to background ratios (TBRs) for pseudotumour lesions relative to venous blood pool1 following immunomodulatory and corticosteroid therapy. Furthermore, we suggest a protocol to optimize 18FDG-PET/CT imaging in patients with IgG4 disease with the aim of improving detection of life-threatening cardiac manifestations.
Original language | English |
---|---|
Article number | e014314 |
Pages (from-to) | 695-697 |
Number of pages | 3 |
Journal | Circulation: Cardiovascular Imaging |
Volume | 15 |
Issue number | 9 |
DOIs | |
Publication status | Published - 2022 |